Clears blocked nose & sinuses

Chronic inflammation of the nose and sinuses — congestion, discharge and loss of smell that persists for months.

Allergic signaling increases it.

Chronic rhinosinusitis with nasal polyps is a predominantly type 2 inflammatory disease of the nasal cavity and paranasal sinuses, and the same receptor that drives eczema drives it: dupilumab binds IL-4Rα, the shared receptor component for IL-4 and IL-13. In the phase 3 SINUS-24 and SINUS-52 trials (724 patients, on background intranasal corticosteroids) it reduced polyp size, sinus opacification and symptom severity against placebo — nasal congestion improved 57% and 51% versus 19% and 15% on placebo — and it is now an approved indication (PMC9081188, PMC11161870). Note: this is the polyp-forming, type-2 form of sinus disease. An infectious or structural blocked sinus is a different problem and this pathway does not describe it. PMC9081188

Immune support reduces it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Calms histamine response increases it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Skin reduces it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Cell migration switch increases it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Pathogen tripwire increases it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Inflammatory signaling increases it.

C. acnes promotes inflammation via TLR2 and TLR4; TLR signals induce NF-kB-dependent expression of NLRP3, pro-IL-18 and pro-IL-1beta. Androgens raise sebum secretion, triggering acne. doi 10.21037/atm-22-1362 · PMC2904443

Calms body-wide inflammation increases it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Calms inflammation increases it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Oxidative stress increases it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses (PMC11059040; PMC12263562; PMC11045947; PMC11897119; PMC12021798). Verbatim: “Our findings suggest that the accumulation of ROS plays a critical role in the pathogenesis of CRSwNP”. doi 10.1177/19458924251386929 · PMC11059040

Gut barrier reduces it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Innate immune sensor increases it.

C. acnes promotes inflammation via TLR2 and TLR4; TLR signals induce NF-kB-dependent expression of NLRP3, pro-IL-18 and pro-IL-1beta. Androgens raise sebum secretion, triggering acne. doi 10.21037/atm-22-1362 · PMC2904443

Tissue remodeling reduces it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

Lowers cortisol reduces it.

This is the same axis as eczema, and it splits the same way: type 2 endotypes are IL-4/IL-5/IL-13-driven and eosinophilic, while non-type-2 endotypes ARE driven by increased Th1 and Th17 responses, resulting in elevated neutrophil levels. Two endotypes, two cell types, two nodes. And the intervention evidence is unusually direct: dupilumab (IL-4Ralpha inhibitor) reduces polyp burden and restores smell, while MEPOLIZUMAB (anti-IL-5) and OMALIZUMAB (anti-IgE) address specific endotypes - three biologics, three targets, three endotype-matched responses. PMC11059040

It reduces Sleep.

Nasal congestion and obstruction disrupt sleep - a named quality-of-life consequence. PMC12446768

It reduces Mood.

CRS impairs quality of life through headaches, congestion and hyposmia. PMC12446768

It increases Eases allergy load.

The united airway: respiratory function was significantly lower in patients with eosinophilic CRS without an asthma diagnosis, suggesting an eosinophilic united airway disease. Upper-airway inflammation measurably affects the lower airway in people who do not have asthma. PMC12446768

It reduces Memory & focus.

Hyposmia and congestion impair concentration. Low - a symptom-burden arm. PMC12446768

It reduces Immune support.

Barrier disruption facilitates microbial colonization and Staphylococcus aureus biofilm persistence. PMC12446768

Lung Power (Respiratory Capacity) →